Clinical Study

Trial Of Parkinson’S And Zoledronic Acid

Posted Date: Apr 30, 2021

  • Investigator: Alberto Espay
  • Specialties: Movement Disorders, Neurology, Parkinson's Disease
  • Type of Study: Drug

This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.


• Men And Women Age 60 Or Older. • Current Parkinson’S Disease Or Neurodegenerative Parkinsonism Diagnosis (Including Progressive Supranuclear Palsy, Multiple System Atrophy, Cortical Basal Degeneration, Vascular Parkinsonism, Dementia With Lewy Bodies Or Another Form Of Neurodegenerative Parkinsonism) • Not Confined To Bed Or Wheel Chair • Willing And Able To Continue In Follow-Up For Up To 5 Years • Willing And Able To Provide Informed Consent. A Legally Authorized Representative May Provide Informed Consent For Those Who Are Unable To Consent For Themselves.


Parkinson's Disease, Neurology, Espay

For More Information:

Christina Gruenwald

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.